3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 1
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Hepatocellular
2
Rectal Neoplasms
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Sorafenib
42
lenvatinib
21
Fluorouracil
16
atezolizumab
15
Oxaliplatin
14
Bevacizumab
13
Doxorubicin
12
Radiosurgery
11
Leucovorin
11
Radiofrequency Ablation
10
Ethiodized Oil
10
pembrolizumab
7
Folfox protocol
7
sintilimab
6
durvalumab
6
Radiotherapy
6
Nivolumab
6
Epirubicin
6
Cisplatin
6
tremelimumab
5
Gemcitabine
5
apatinib
4
Embolization, Therapeutic
4
tislelizumab
3
camrelizumab
3
cabozantinib
3
Tenofovir
3
Pharmaceutical Preparations
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Hepatocellular
×
brivanib
×
Clear all
NCT00908752
2019-12-02
BRISK TA
Bristol-Myers Squibb
Phase 3
Completed
734 enrolled
NCT01108705
2015-10-12
BRISK-APS
Bristol-Myers Squibb
Phase 3
Terminated
87 enrolled